Disease modifying anti-arthritic activity of 2-methoxyestradiol
The present invention relates a composition for treating rheumatic diseases. The composition comprises a compound having the formula wherein R a is selected from —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH 2 CH 3 , —CCCH 3 , —CHCH—CH 3 , or CH 2 —CHCH 2 ; and one or more anti-rheumatic agents. A method of using the composition for treating rheumatic diseases in humans and animals is also disclosed.
1. A method of treating rheumatic diseases comprising administering to a human or an animal an effective rheumatic arthritis-treating amount of
a) a therapeutic agent having the structure
wherein R a is —OCH 3 ; and,
b) a second compound being methotrexate;
wherein the first therapeutic agent and the second compound are administered in synergistic amounts for treating rheumatoid arthritis; and, wherein the synergistic amounts result in an inhibition of arthritic score that is greater than an expected inhibition of arthritic score.
2. The method of claim 1 , wherein the therapeutic agent and the anti-rheumatic agent are administered in a single formulation.
3. The method of claim 1 , wherein the therapeutic agent and the anti-rheumatic agent are administered in two or more separate formulations.
4. The method of claim 1 , wherein said first therapeutic agent and said methotrexate are administered together.
5. The method of claim 1 , wherein said first therapeutic agent and said methotrexate are administered separately.
6. The method of claim 1 , wherein the first compound is administered in an amount of approximately 100 mg/kg of body weight and the second compound is administered in an amount of approximately 1 mg/kg of body weight.
7. A composition for treating rheumatic diseases comprising;
a) a compound having the formula
wherein R a is —OCH 3 ; and
b) a second compound being methotrexate,
wherein the first and second compounds are provided in synergistic amounts effective for treating rheumatoid arthritis; and, wherein the synergistic amounts result in an inhibition of arthritic score that is greater than an expected inhibition of arthritic score.
8. The composition of claim 7 , wherein the composition comprises:
approximately 100 mg/kg of body weight of the first compound; and
approximately 1 mg/kg of body weight of the second compound.